國立虎尾科技大學 |

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia/ edited by Masahiro Kizaki.
其他作者:	Kizaki, Masahiro.
面頁冊數:	VIII, 193 p. 26 illus., 20 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Hematology. -
電子資源:	https://doi.org/10.1007/978-4-431-55714-2
ISBN:	9784431557142

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia[electronic resource] /edited by Masahiro Kizaki. - 1st ed. 2016. - VIII, 193 p. 26 illus., 20 illus. in color.online resource.

1. Identification and Biology of CML Stem Cells.- 2. Molecular Mechanisms of CML Stem Cell Maintenance -- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.- 4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.- 5. Biomarkers for Determining the Prognosis of CML -- 6. Updated European Leukemia Net Recommendations for the Management of CML -- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis -- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs -- 9. Role of New TKIs and Combinations with Interferon-α for the Treatment of CML -- 10. Safety Profiles of First-Line TKIs and Managing Adverse Effects -- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance -- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

ISBN: 9784431557142

Standard No.: 10.1007/978-4-431-55714-2doiSubjects--Topical Terms:

645254
Hematology.

LC Class. No.: RB45

Dewey Class. No.: 616.15

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
LDR:03360nam a22003975i 4500 001 979642
003 DE-He213
005 20200702175443.0
007 cr nn 008mamaa
008 201211s2016 ja | s |||| 0|eng d
020 $a 9784431557142 $9 978-4-431-55714-2
024 7 $a 10.1007/978-4-431-55714-2 $2 doi
035 $a 978-4-431-55714-2
050 4 $a RB45
072 7 $a MJF $2 bicssc
072 7 $a MED038000 $2 bisacsh
072 7 $a MJF $2 thema
082 0 4 $a 616.15 $2 23
245 1 0 $a Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia $h [electronic resource] / $c edited by Masahiro Kizaki.
250 $a 1st ed. 2016.
264 1 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2016.
300 $a VIII, 193 p. 26 illus., 20 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1. Identification and Biology of CML Stem Cells.- 2. Molecular Mechanisms of CML Stem Cell Maintenance -- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.- 4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.- 5. Biomarkers for Determining the Prognosis of CML -- 6. Updated European Leukemia Net Recommendations for the Management of CML -- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis -- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs -- 9. Role of New TKIs and Combinations with Interferon-α for the Treatment of CML -- 10. Safety Profiles of First-Line TKIs and Managing Adverse Effects -- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance -- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.
520 $a Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.
650 0 $a Hematology. $3 645254
650 0 $a Oncology . $3 1253469
650 2 4 $a Oncology. $3 593951
700 1 $a Kizaki, Masahiro. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103263
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9784431557135
776 0 8 $i Printed edition: $z 9784431557159
776 0 8 $i Printed edition: $z 9784431562559
856 4 0 $u https://doi.org/10.1007/978-4-431-55714-2
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)